Therefore, given the multitude of indications for the relevant oncogenic role of LGR4, it remained valuable to further investigate the clinical potential of anti-LGR4 monoclonal antibodies specifically in cancer patients that harbored LGR4 alterations, which would hopefully provide more insight beneficial to the development of novel treatment strategies against LGR4 driven cancer. Here, LGR4 is linked to cancer.